Splash Beverage Group, Inc. (EDVA) AI Stock Analysis
EDVA AI stock analysis summary
AI ResearchSplash Beverage Group, Inc. (EDVA) is a biotechnology company developing cannabinoid health science therapies and wellness products. The company generated $32,090 in trailing twelve month revenue with an operating margin of -45159.1%. As of June 30, 2026, the company held $242,702 in cash and short-term investments alongside negative shareholders' equity of -$15.7M.
- Market cap
- $1.6M
- Revenue (TTM)
- $32,090
- P/E
- —
- 1Y return
- -98.2% S&P 500 16.8%
- Avg. target
- —
Bull case
- The company narrowed its annual cash burn, improving free cash flow from -$14.2M in FY2022 to -$4.8M in FY2025.
- Gross margin recovered to positive territory at 23.1% in FY2025 after falling to -15.0% in FY2024.
- The stock trades at a price-to-book multiple of 0.2x as of October 16, 2026.
Bear case
- Revenue collapsed at an annualized 3-year CAGR of -84.1%, falling from $18.1M in FY2022 to $73,066 in FY2025.
- Operating margin was severely negative at -45159.1% over the trailing twelve months ended June 30, 2026.
- Liquidity is under severe pressure with a current ratio of 0.05 and cash and short-term investments of only $242,702 as of June 30, 2026.
What Splash Beverage does
Endovia Health Sciences, Inc., formerly known as Splash Beverage Group, Inc., develops a diversified cannabinoid health sciences platform that translates science into regulated therapies and trusted health and wellness products for people and animals. The company operates across Ireland, the United Kingdom, Australia, and Latin America. Its product portfolio includes CannEpil, a pharmaceutical-grade cannabinoid formulation comprising cannabidiol and tetrahydrocannabinol isolates delivered in an oral liquid solution. Based in Fort Lauderdale, Florida, the company has 1 employee and trades on the NYSE American.
Growth and profitability
Revenue has declined significantly from $18.1M in FY2022 and $18.9M in FY2023 down to $801,273 in FY2024 and $73,066 in FY2025, reflecting a 3-year revenue CAGR of -84.1%. Net losses expanded from -$21.7M in FY2022 to -$25.2M in FY2025, with net margin reaching -34537.0%. Gross margin was 23.1% in FY2025, rebounding from -15.0% in FY2024. For the trailing twelve months ended June 30, 2026, revenue stood at $32,090, while EPS was -$21.94 and operating margin was -45159.1%.
Balance sheet and cash flow
As of June 30, 2026, the company held $242,702 in cash and short-term investments against total assets of $1.1M. Shareholders' equity remained negative at -$15.7M, with a current ratio of 0.05. Operating cash flow in FY2025 was -$4.8M, matching a free cash flow of -$4.8M, compared to free cash flow of -$7.8M in FY2024 and -$10.2M in FY2023.
Valuation and performance
At a last close of $0.15 on October 16, 2026, EDVA had a market cap of $1.6M and an enterprise value of $7.6M. The stock traded at a price-to-sales multiple of 50.4x and an EV to revenue multiple of 235.7x, both well above the 4.1x price-to-sales median of its US-listed Healthcare peers. Its price-to-book ratio was 0.2x. Over the trailing 1-year period, the stock dropped 98.2%, underperforming the S&P 500 return of 16.8%, and is down 100.0% over 5 years compared to an 83.0% gain for the benchmark.
What analysts expect
No analyst rating counts or consensus price targets are currently published for the stock. Regarding earnings track record, the company achieved 1 beat over the last 4 quarters, while reporting a trailing twelve month EPS of -$21.94 as of June 30, 2026. The next scheduled earnings report date is November 18, 2026.
Key risks and what to watch
- Shareholders' equity stands at -$15.7M alongside total assets of $1.1M as of June 30, 2026, indicating capital structure distress.
- Trailing twelve month revenue reached only $32,090, while net losses remained high at -$25.2M in FY2025.
- The company employed only 1 worker as of October 16, 2026, posing operational execution risks.
- The stock declined 98.2% over the past year and trades 87.5% below its 200-day average.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this EDVA AI stock analysis
This page is an AI-written research summary of Splash Beverage Group, Inc. (EDVA). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: EDVA income statement, EDVA balance sheet, EDVA key metrics, EDVA chart. See the EDVA stock overview for the latest quote and news.
EDVA AI stock analysis FAQ
What does Splash Beverage Group (Endovia Health Sciences) do?
The company develops a cannabinoid health sciences platform providing regulated therapies and wellness products such as CannEpil across Ireland, the UK, Australia, and Latin America.
What was EDVA's revenue in the most recent fiscal year?
In FY2025, revenue was $73,066, representing a 90.9% decline from $801,273 reported in FY2024.
Does EDVA pay a dividend?
EDVA does not pay a dividend.
What is the current liquidity position of EDVA?
As of June 30, 2026, EDVA held $242,702 in cash and short-term investments with a current ratio of 0.05 and negative shareholders' equity of -$15.7M.
When is EDVA's next earnings date?
The next earnings date for EDVA is scheduled for November 18, 2026.